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Abstract
Background: Recent researches have been focusing on mucosal immune adjuvants, which play the key roles in
mucosal immunization and have become the limitation for non-injected vaccine development. Escherichia coli heat-
labile enterotoxin B subunit (LTB) was regarded as a promising mucosal adjuvant for its nontoxicity and potent
activity. LTB preparation issues have always been recurring, in part owing to that the recombinant LTB expressed by
E. coli does not act as its native form.
Results: We constructed an engineered Lactococcus lactis strain using a food-grade expression system. The LTB
secreted by the engineered strain was detected in the culture supernatant, constituting 10.3% of the supernatant
proteins, and recognized by mouse anti-LTB antibodies. The engineered strain, co-administered orally to SPF BALB/c
mice with a H. pylori vaccine candidate expressing Lpp20 antigen, could significantly enhance the Lpp20-induced
mucosal SIgA antibody responses against H. pylori.
Conclusions: This is the first report that LTB was efficiently produced and delivered via using a food-grade
lactococcal expression system, which offers a novel production and utilization mode of this crucial mucosal
adjuvant. The engineered L. lactis strain secreting LTB has considerable potential for oral vaccine formulation owing
to its outstanding safety, adjuvant activity and high-level production.
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Highlights
1. This is the first report that LTB was efficiently
produced and delivered via using a food-grade lacto-
coccal expression system.
2. This study offers a novel production and utilization
mode of this crucial mucosal adjuvant.
3. The engineered L. lactis strain secreting LTB has
considerable potential for oral vaccine formulation
owing to its outstanding safety, adjuvant activity and
high-level production.
Background
Gastroenteric infections cause an estimated two mil-
lion deaths worldwide per year, and remain severe
public health issues [1, 2]. As antibiotic resistance has
been continually increasing, researches currently focus
on developing vaccines against the causative agents,
such as Helicobacter pylori, Shigella and enterotoxi-
genic E. coli (ETEC), for which no commercial vac-
cines are available [1].
Presently, most commercial vaccines are administered
by parenteral routes [3]. However, recent studies demon-
strated mucosal vaccination as the most effective strat-
egy against the pathogens that colonize or invade
mucosa to initiate lesions [3–5]. Although parenteral im-
munizations can protect against causative agents
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parasitizing host tissues via stimulation of serum anti-
body and cellular immune responses, they can hardly
elicit mucosal immunity against noninvasive pathogens
[3, 6]. Mucosal vaccination can stimulate secretory anti-
body responses preventing infection by the pathogens
from the mucosal surface [5]. Additionally, mucosal im-
munizations have the advantages of simple manipula-
tion, less invasion, lowered risks of disease transmissions
and ease of manufacture over parenteral inoculations.
However, mucosal vaccinations with antigens alone are
commonly insufficient to induce marked immune re-
sponses, unless the antigens can reach the mucosal in-
ductive sites as cholera toxins [3, 7]. As proved, mucosal
adjuvants or microbial delivery vectors are required for
effective mucosal immune responses [8]. Therefore, re-
cent researches have emphasized screening and prepar-
ation of adjuvants and the biotic delivery vehicles which
possess adjuvant activity [3].
E. coli heat-labile enterotoxin B subunit (LTB) is a
promising mucosal adjuvant, owing to its nontoxicity
and potent mucosal adjuvant activity [9]. Nevertheless,
LTB preparation issues have always been existing be-
cause it is impractical to purify LTB from ETEC for pro-
duction of vaccines, and the activity of recombinant LTB
(rLTB) was greatly affected by the expression hosts
employed. Previous studies have indicated that prepar-
ation of LTB by using a E. coli expression system are not
only inefficient but also costly [6]. The reasons involve
the recurring formation of insoluble inclusion bodies,
lower yields of bioactive rLTB, the cost of protein purifi-
cation and the risk of pollution with unbeneficial bacter-
ial components like lipopolysaccharide.
To address these issues, such bacteria as attenuated
pathogens and probiotics have been exploited as expres-
sion hosts and live vectors for LTB production and deliv-
ery. A study compared expression efficacy of rLTB in
Pichia pastoris with that in E. coli, demonstrating that a
higher expression level and adjuvant activity of rLTB
could be obtained by using P. pastoris as the expression
host [6]. Another study proved that LTB expressed in fu-
sion with antigens in engineered Lactobacillus can sig-
nificantly enhance the local and systemic immune
responses to the antigens [10, 11]. Recently, increasing
evidences supported that food-grade L. lactis expression
systems, through expression and delivery of antigens/ad-
juvants, are promising oral vaccine vectors, particularly
owing to their outstanding safety, avoidance of protein
purification, reduced antigen degradation and efficient
delivery of immunogens to the mucosal inductive sites
[12, 13]. However, successful expression of LTB in food-
grade L. lactis has not been reported to date. Therefore,
construction of a food-grade L. lactis strain producing
LTB should be a considerable step toward the goal of ef-
fective and safe mucosal vaccines.
In this work, a food-grade L. lactis strain was genetic-
ally engineered for production and delivery of LTB, and
its immune adjuvant activity was evaluated by oral vac-
cination of mice with the engineered strain and a
Lpp20-based H. pylori vaccine candidate. The observa-
tions of this study demonstrate a novel efficient produc-
tion and utilization mode of LTB, which forms a crucial
basis for mucosal vaccine formulation.
Methods
Bacterial strains, plasmids and growth conditions
The bacteria and plasmids are shown in Additional file 1.
The bacterial cultivation conditions were as described pre-
viously [12, 14]. SPF BALB/c mice, aged 6 weeks, were
purchased from Henan Experimental Animal Center
(Zhengzhou, China).
Polymerase chain reaction of ltB gene
The ltB gene was amplified by PCR from the plasmid
pMAL-c2x-mlt63 using Pyrobest DNA polymerase
(TaKaRa, China). A pair of oligonucleotide primers was de-
signed based on the published sequence (GenBank
EF057802). The sequences of the primers were 5’-
CAGTCGGCATGCGCTCCCCAGTCTATTAC-3’ (Sense)
and 5’-CGCTCTAGACTAGTTTTCCATACTGATTG-3’
(Antisense) with the endonuclease sites SphI and XbaI
shown in bold letters, respectively. The PCR profile in-
cluded 30 cycles of 94 °C for 1 min, 55 °C for 30 s and 72 °
C for 2 min.
Construction of recombinant L. lactis strains
The ltB gene was ligated with TA cloning vector
pMD19-T and used to transform E. coli DH5α by heat
shock. The ltB gene fragment was collected by digestion
of pMD19-T-ltB using SphI and XbaI (TaKaRa, China),
ligated with plasmid pNZ8149-SP (GenBank KY385376),
and used for transformation of L. lactis NZ3900 by elec-
trophoration [12]. The recombinants were obtained by
Elliker medium selection, and identified by restriction
digestion and gene sequencing as reported before [12].
The recombinant NZ3900 strain carrying ltB gene was
referred to as L. lactis NZ3900/pNZ8149-SP-ltB.
LTB expression and western blotting assays
The expression of LTB in NZ3900/pNZ8149-SP-ltB was
induced using 25 ng/ml nisin (Sigma, USA) as inducer
under the conditions as previously described [12].
Samples of the culture supernatant were prepared
from 50 ml of culture. The supernatant was obtained by
centrifugation at 10,000 rpm for 20 min at 4 °C, and fil-
tered through 0.22 μm filter. The proteins in the filtrate
were precipitated by adding trichloroacetic acid (10%, v/
v), incubating at 4 °C for 16 h and centrifugation at
10,000 rpm for 30 min at 4 °C. The pellet was
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resuspended in 8 ml acetone, centrifugated at
10,000 rpm for 20 min at 4 °C, then kept in fume hood
at room temperature until dry. The protein sample was
added 360 μl PBS, kept at 4 °C for 3 h, and centrifugated
at 10,000 rpm 4 °C for 10 min. The supernatant was col-
lected and used as samples of the culture supernatant.
Samples of bacterial cell lysates were processed as de-
scribed before [12].
SDS-PAGE and western blotting assays were per-
formed using mouse anti-LTB antibody (Abcam, USA)
as the primary antibody as previously reported [12].
Oral vaccination of mice
The mice were assigned at random into three groups of
10 each. For Lpp20 group and Lpp20 + LTB group, the
mice were treated by gavage with cell suspensions at a
dose of 300 μl of NZ3900/pNZ8149-SP-lpp20 (1 ×
1011 CFU/ml) and a mixture of NZ3900/pNZ8149-SP-
lpp20 (1 × 1011 CFU/ml) and NZ3900/pNZ8149-SP-ltB
(1 × 1011 CFU/ml), respectively, on day 0, 7, 14, 21, 28
and 35. For PBS group, mice were given equal volumes
of PBS instead of the cell suspensions.
Blood and intestinal feces sampling
Seven days after the last vaccination, blood and intestinal
feces were collected for half number of the mice from all
the groups. The blood samples were fetched from orbital
sinus and kept at 4 °C for 16–20 h, and then the sera
were separated and stored in aliquots at −20 °C. For
sampling intestinal feces, the mice were sacrificed by
spinal dislocation, 100 mg of feces was fetched from the
intestine for each mouse, and then 1 ml of PBS contain-
ing proteinase inhabitor (Phenylmethanesulfonyl fluor-
ide, 0.1 mM) was injected by the duodenum to wash the
intestinal wall. The eluate was recovered, mixed with the
feces and kept at 4 °C for overnight (14–16 h). The
supernatant of the mixture was separated via centrifuga-
tion at 12,000 rpm for 10 min, and stored at −20 °C as
ELISA samples.
ELISA detection of IgG and SIgA antibodies
The H. pylori-specific serum IgG and fecal SIgA anti-
bodies were quantified by ELISA as described before [12].
Briefly, 96-well microplates (Beijing Solarbio, China) were
coated with soluble H. pylori somatic proteins. The ELISA
signals were developed using biotinylated goat anti-mouse
IgG (Abcam, USA), goat anti-mouse SIgA (Abcam, USA)
and p-nitrophenyl phosphate (PNPP) substrate (Beijing
Solarbio, China). The absorbances of the wells at 450 nm
(OD450) were measured using a Microplate Reader (Tecan
Sunrise, CH), and designed as indicators of the specific
sIgA and IgG levels.
Statistical analysis
The measurement data were presented as means ± stan-
dard deviation xð  sÞ: The significance of the difference
among the groups was tested using Kruskal-Wallis tests,
while the pairwise comparisons of mean values were
carried out using the Mann-Whitney U test with the aid
of software SAS9.13. The difference was considered as sig-
nificant at P <0.05.
Results
Genetic engineering of L. lactis
The PCR product of ltB gene was 334 bp in length, and
100% identical in nucleotide sequence to the published
E. coli ltB gene (GenBank JX504011.1). The plasmids
were isolated from the L. lactis transformants, and iden-
tified by restriction enzyme digestion. Gene sequencing
confirmed that the ltB gene was exactly cloned down-
stream of the nisin controlled promoter (Pnis) within
the expression vector pNZ8149-SP, generating
pNZ8149-SP-ltB. The schematic diagram of pNZ8149-
SP-ltB was shown in Fig. 1.
Expression and immunoreactivity of Lpp20
To determine inducible expression of LTB in L. lactis,
the cell lysates and culture supernatant were analyzed by
SDS-PAGE and western blots. As results, SDS-PAGE
analysis showed that a dense protein band was present
at approximately 13 kDa position in the culture super-
natant of NZ3900/pNZ8149-SP-ltB, while absent at the
corresponding position in the controls (Fig. 2a). The
Fig. 1 The schematic maps of pNZ8149-SP-ltB designed using software
Omiga 2.0. Pnis, nisA promoter; SP, signal sequence of usp45 gene; ltB,
ltB gene coding region; T, terminator; repA and repC, replication gene
A and C; lacF, lacF gene as selection signature
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percentage of LTB reached 10.3% in the culture super-
natant proteins of the engineered stain.
Western blotting analysis showed that the 13 kDa protein
in the culture supernatant of NZ3900/pNZ8149-SP-ltB
could be recognized by the mouse anti-LTB antibodies,
while there was no positive band at the corresponding pos-
ition in the lanes of NZ3900/pNZ8149-SP samples as nega-
tive controls (Fig. 2b).
Immunization of mice and antibody assays
The L. lactis NZ3900/pNZ8149-SP-lpp20 and NZ3900/
pNZ8149-SP-ltB were induced with nisin as mentioned
above. The mice of the immunized groups were orally
inoculated with the induced NZ3900/pNZ8149-SP-lpp20
alone and its mixture with NZ3900/pNZ8149-SP-ltB, re-
spectively, while the control group was treated with PBS.
On day 7 after the final vaccination, the serum and in-
testinal feces were sampled, and tested for H. pylori-spe-
cific antibodies by ELISA assays. The results are shown
in Additional file 2 and Fig. 3. The group treated with
NZ3900/pNZ8149-SP-lpp20 alone had enhanced anti-H.
pylori serum antibody responses, but no significantly ele-
vated intestinal SIgA level, compared with the PBS
group. The vaccination with the mixture of the two L.
lactis strains evoked significantly elevated SIgA antibody
level, and insignificantly lowered the serum IgG re-
sponse, as compared with the group administered with
Fig. 2 Analysis of cell lysate and culture supernatant proteins of the nisin-induced L. lactis strains. The arrows indicate the expressed UreB. a SDS-
PAGE. Lane M, protein markers; lane 1, 2, 3, cell lysates of NZ3900, NZ3900/pNZ8149-SP and NZ3900/pNZ8149-SP-ltB, respectively; lane 4, 5, culture
supernatant of NZ3900/pNZ8149-SP and NZ3900/pNZ8149-SP-ltB, respectively. These figures showed that the recombinant LTB was expressed as
a secreted protein. b Western blotting assays. L. lactis NZ3900/pNZ8149-SP was used as the negative control, while mouse anti-LTB antibodies as
the primary antibodies for detection of LTB. Lane M, protein markers; lane 1, 2, culture supernatant of NZ3900/pNZ8149-SP-ltB and NZ3900/
pNZ8149-SP, respectively; lane 3, 4, cell lysates of NZ3900/pNZ8149-SP-ltB and NZ3900/pNZ8149-SP, respectively. These figures showed that the
expressed LTB was detectable only in the culture supernatant of NZ3900/pNZ8149-SP-ltB, and possessed immunoreactivity with the commercial
anti-LTB antibody
Fig. 3 OD450 values of ELISA tests for H. pylori-specific serum IgG
and intestinal SIgA levels. The Lpp20 group and Lpp20 + LTB group
were vaccinated with L. lactis NZ3900/pNZ8149-SP-lpp20 and the
mixture of NZ3900/pNZ8149-SP-lpp20 and NZ3900/pNZ8149-SP-ltB,
respectively, while the PBS group, as the control, was treated with
PBS. One week after oral immunization, blood sampling was
performed for half number of the mice of all the groups. The serum
(1:10 diluted) and fecal samples were tested for H. pylori-specific
antibodies by ELISA. Bars, mean OD450 value; error bars, standard
deviation; Δ the value was significantly higher than that for the PBS
group (P < 0.05); * the value was significantly different from those for
the other two groups (P < 0.05)
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NZ3900/pNZ8149-SP-lpp20 alone. The results demon-
strated the adjuvant activity of the engineered L. lactis
expressing LTB to promote mucosal immune responses.
Discussion
As proved, the species of bacteria as expression hosts
might greatly affect the bioactivity of recombinant ex-
pression products [6]. Through screening of various mi-
crobial expression systems, it is possible to establish an
efficient method for production and utilization of LTB.
Nevertheless, although studies have demonstrated the
potential of LTB as mucosal adjuvant and accumulated
evidences proved L. lactis to be a safe vaccine vehicle,
expression and delivery of LTB using a food-grade L. lac-
tis strain have not been reported yet. Therefore, success-
fully engineering a food-grade L. lactis strain to secret
LTB can be a crucial basis for mucosal vaccine
development.
L. lactis NZ3900/pNZ8149-SP is a food-grade nisin-
controlled expression system, which was constructed in
our previous study by introducing a gene fragment en-
coding the signal peptide of L. lactis Usp45 protein into
pNZ8149 for capacity of secretory expression of heterol-
ogous genes [12]. In this work, the ltB gene was inserted
downstream of the nisin controlled promoter within
pNZ8149-SP, and expression of LTB was achieved by in-
ducement with food-grade subtoxic amount of nisin. All
the components of L. lactis NZ3900/pNZ8149-SP-ltB,
except for the target gene ltB, possess food-grade safety,
suggesting the extremely high safety of the engineered
strain as the LTB producer.
As reported, the L. lactis expression efficiency of
heterologous protein can be rather low, and thus the ex-
pression products in certain studies were detectable by
western blots, but not by SDS-PAGE [15, 16]. In this
work, the expressed LTB was visual as the predominant
band in the SDS-PAGE pattern, constituting 10.3% of
the culture supernatant extracts of the engineered L. lac-
tis. The expression efficacy was much higher than those
reported [12, 15–17]. The mechanism underlying this
phenomenon might include the diversity of the heterol-
ogous genes in genetic codon constitution. The LTB
expressed in L. lactis had a molecular weight of approxi-
mately 13 kDa, corresponding to that deduced from the
nucleotide sequence (GenBank JX504011.1). Western
blotting assays showed that LTB produced by the engi-
neered L. lactis strain retained potent antigenicity. These
findings indicate that the engineered strain culture can
be a novel source of LTB, from which LTB can be
obtained and utilized without protein purification and
the risk of pollution with toxic components from the
commonly used expression hosts, such as E. coli and
Salmonella spp..
A recurring issue on heterogeneous expression is that
the recombinant products might lose bioactivity of the na-
tive proteins. Although the molecular basis of LTB adju-
vant properties remains unclear, it might be included that
LTB interacts with such receptors as GM1-ganglioside ac-
celerating uptake of the toxic subunit A into the epithelial
cells [6, 18]. In the present study, it was observed that vac-
cination of mice with L. lactis expressing Lpp20 was cap-
able of arousing remarkable serum IgG antibody
responses, but failed to induce significantly elevated intes-
tinal specific SIgA antibody levels, as compared with the
group given PBS, indicating that without the aid of suit-
able mucosal adjuvants, the employed L. lactis strain pro-
ducing Lpp20 can hardly evoke notable mucosal immune
responses. Similarly, a previous study showed that a L. lac-
tis strain producing H. pylori UreB antigen was unable to
elicit marked immune responses in mice [17]. The adju-
vant activity of the engineered strain secreting LTB has
been proved by the observations that the group received
the mixture of the two engineered L. lactis strains express-
ing Lpp20 and LTB, respectively, had significantly elevated
sIgA antibodies, in comparison with the group given the
Lpp20-producing strain alone. Since mucosal SIgA anti-
bodies have the key roles in immune protection against
the pathogens invading human tissues by the mucosal sur-
face, the findings of our study suggest that the engineered
strain secreting LTB might markedly enhance the immune
protective efficacy of the co-administered antigens [19].
Interestingly, accompanying with the enhanced muco-
sal SIgA, the serum IgG antibodies seemed to be sup-
pressed in the mice immunized with the mixture of the
two L. lactis strains. This result suggests that the LTB-
secreting L. lactis might modulate the systemic and mu-
cosal immune responses with opposite effects. The
mechanism and its implication for vaccine designs need
further investigation.
In recent decades, although in most countries the use
of genetically modified organisms (GMOs) was prohib-
ited or heavily regulated, it has been proposed to change
the present regulations [20, 21]. In fact, the amount of
commercially available GMOs has been continuously ris-
ing in recent years [22]. It is hopeful for the food-grade
L. lactis engineered here to be used in pharmacy and
food industry in future.
Conclusion
Taken together, this is the first report that E. coli LTB
was efficiently produced and delivered via using a food-
grade lactococcal expression system, which offers a novel
production and utilization mode of this crucial mucosal
adjuvant. The engineered L. lactis strain secreting LTB
has considerable potential for oral vaccine formulation,
owing to its outstanding safety, adjuvant activity and
high-level production.
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